AbbVie's emraclidine setback in phase 2 trials impacts neuroscience pipeline, benefitting Bristol Myers Squibb's Cobenfy in muscarinic drug class. Learn more on ABBV stock here.

AbbVie said the impairment charge is related to last year’s $8.7 billion bet on Cerevel following the failure of the deal’s key drug candidate, emraclidine, a schizophrenia treatment .

The failure of Cerevel's emraclidine in schizophrenia will cost AbbVie an impairment charge of about $3.5 billion, the pharma said in a Jan. 10 filing with the Securities and Exchange Commission ...

AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. The ...

Investigators evaluated emraclidine in patients with schizophrenia who are experiencing an acute exacerbation in two placebo-controlled Phase II trials, which included EMPOWER-1 and EMPOWER-2. The ...

AbbVie (NYSE:ABBV) shares dropped about 11% after its late-stage trials investigating emraclidine as an oral monotherapy treatment for adults with schizophrenia experiencing acute exacerbation of ...

AbbVie’s treatment, emraclidine, which it got the drug through its $9 billion acquisition of Cerevel Therapeutics, failed to significantly help patients. Skip to Main Content.

Emraclidine is also in phase 1 for Alzheimer's disease psychosis, which also has FDA Fast Track designation. However, this is a much smaller market than the schizophrenia indication would have been.

Emraclidine performed worse than in Cerevel’s phase 1b trial, when the biotech tracked improvements on PANSS of 19.5 and 17.9 points, but placebo response was the main difference between the ...

AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their ...

Emraclidine is a potential novel M4-selective positive allosteric modulator (PAM) in development for schizophrenia and Alzheimer's disease psychosis as a once-daily medication without the need ...